What is CJC-1295?
CJC-1295 is a synthetic GHRH analog. The DAC (drug affinity complex) variant binds to serum albumin to extend its half-life to several days, while the no-DAC version (Modified GRF 1-29) has a half-life of approximately 30 minutes. It is frequently paired with a GH secretagogue like Ipamorelin.
Mechanism of action
CJC-1295 stimulates the anterior pituitary to release growth hormone in pulsatile fashion. The DAC modification protects it from enzymatic degradation, producing a sustained 'GH bleed' rather than discrete pulses.
Researched benefits
- Increased endogenous GH and IGF-1 in clinical studies
- Improved lean body composition signals
- Reported improvements in sleep architecture
- Recovery and connective-tissue support
Researched dosage
Most research protocols use 100–300 mcg administered 1× per day via subcutaneous injection. CJC-1295 no-DAC is typically used at 100 mcg up to 3× daily; CJC-1295 with DAC is used once or twice weekly at 1–2 mg.
A typical cycle runs 8 weeks on, then 4 weeks off before reassessment.
Use the calculator below to convert your target CJC-1295 dose into exact insulin-syringe units.
Reconstitution & storage
A standard 2 mg vial reconstituted with 2 mL of bacteriostatic water yields 1000 mcg/mL. Lyophilized stable at 2–8°C. Reconstituted product should be refrigerated.
Side effects & considerations
- Flushing and warmth after injection
- Tingling or numbness in extremities
- Headache, water retention
CJC-1295 stacks
- CJC-1295 / Ipamorelin — paired with Ipamorelin. Synergistic, prolactin-sparing GH pulse. Combining a GHRH analog with a GHRP produces a larger GH pulse than either alone. Ipamorelin is selective and does not elevate cortisol or prolactin.
Selected research
- Sustained growth hormone secretion with CJC-1295 — JCEM, 2006
- Effects of CJC-1295 on serum IGF-I — Endocrine Practice, 2005